XOMA Royalty Corporation (NASDAQ: XOMA) is set to acquire all outstanding shares of LAVA Therapeutics N.V. (NASDAQ: LVTX) through its tender offer for (i) USD $1.04 per share in cash and (ii) a non-transferable contingent value right (CVR) per share representing the right to receive 75% of the net proceeds related to LAVA’s partnered and unpartnered programs. Additionally, shareholders may receive up to $0.23 per CVR based on certain potential liabilities.

Our capital markets, tax, employment, health care and capital markets teams led by Menno Baks and Michel van Agt advised XOMA Royalty Corporation on this strategic transaction.

This acquisition strengthens XOMA Royalty’s economics related to LAVA’s partnered programs investigating the utility of gamma delta bispecific antibodies, which hold significant therapeutic promise for patients. These include JNJ-89853413, targeting CD33 and hematologic cancers (partnered with Johnson & Johnson), and PF-08046052, targeting EGFR and solid tumors (partnered with Pfizer Inc.), both developed using LAVA’s proprietary Gammabody® platform.

XOMA Royalty Corporation is a biotechnology royalty aggregator that plays a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies, maintaining a growing and diversified portfolio of assets.

LAVA Therapeutics N.V. is a biopharmaceutical company that has developed several clinical-stage bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, including JNJ-89853413 and PF-08046052. Gammabody® is a registered trademark of LAVA Therapeutics N.V.

For more information, please reach out to one of the advisers involved in this transaction.